التفاصيل البيبلوغرافية
العنوان: |
Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study |
المؤلفون: |
Yingkai Xu, Yuan Huang, Zihan Yuan, Wanbing Liu, Li Wang, Lei Liu |
المصدر: |
Frontiers in Cellular and Infection Microbiology, Vol 14 (2024) |
بيانات النشر: |
Frontiers Media S.A., 2024. |
سنة النشر: |
2024 |
المجموعة: |
LCC:Microbiology |
مصطلحات موضوعية: |
COVID-19, Azvudine, composite disease progression outcome, all-cause death, retrospective cohort study, Microbiology, QR1-502 |
الوصف: |
BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research and validation are necessary.MethodsA retrospective cohort study was conducted on COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command from 1 December 2022 to 31 January 2023. We included 132 patients treated with Azvudine and 132 controls after screening and propensity score matching. The primary outcomes including all-cause mortality and a composite outcome of disease progression such as non-invasive respiratory support, invasive respiratory support, admission to intensive care unit (ICU), and death were compared.ResultsAzvudine recipients had a much lower incidence rate of composite disease progression outcome than controls (13.9075/1000 person-days versus 25.7731/1000 person-days, P |
نوع الوثيقة: |
article |
وصف الملف: |
electronic resource |
اللغة: |
English |
تدمد: |
2235-2988 |
Relation: |
https://www.frontiersin.org/articles/10.3389/fcimb.2024.1453234/full; https://doaj.org/toc/2235-2988 |
DOI: |
10.3389/fcimb.2024.1453234 |
URL الوصول: |
https://doaj.org/article/2ca0bba0526c41a2917078c0c43a63bf |
رقم الانضمام: |
edsdoj.2ca0bba0526c41a2917078c0c43a63bf |
قاعدة البيانات: |
Directory of Open Access Journals |